Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
2(66.7%)
N/A
1(33.3%)
3Total
Phase 1(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07470151Not ApplicableRecruiting

Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases

Role: collaborator

NCT05800873Phase 1Recruiting

Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001

Role: lead

NCT06541639Phase 1Recruiting

EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors

Role: collaborator

All 3 trials loaded